文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

连续性静脉-静脉血液滤过联合局部枸橼酸抗凝时两种碳酸氢盐置换液的比较:一项前瞻性随机对照试验

Comparison of two different bicarbonate replacement fluids during CVVH with RCA: a prospective, randomized, controlled trial.
PubMed 文献 · Intensive Care Med · 2025-11-17
一句话结论在CVVH联合局部枸橼酸抗凝患者中,低碳酸氢盐置换液(22 mmol/l)较高碳酸氢盐置换液(30 mmol/l)的pH和HCO3-超出标准范围率更低,酸中毒患者pH正常化时间无显著差异。

该研究为前瞻性、随机、对照、开放标签、交叉、单中心试验,纳入88例接受CVVH联合局部枸橼酸抗凝的患者,随机先接受低碳酸氢盐置换液(LBF,22 mmol/l HCO3-)或高碳酸氢盐置换液(HBF,30 mmol/l HCO3-)48小时,随后交叉至另一液体再治疗48小时。主要观察指标为pH和HCO3-超出标准值的 excursion 率。结果显示HBF组至少一次pH和HCO3- excursion率均高于LBF组,校正OR分别为1.78(95% CI 1.12-2.82;p=0.015)和3.60(95% CI 2.16-5.99;p<0.001)。酸中毒患者pH正常化时间和低HCO3-患者HCO3-正常化时间在两组间无显著差异(p=0.102,p=0.468)。结论认为LBF的pH和HCO3- excursion率显著低于HBF。

要点

  • 在CVVH联合局部枸橼酸抗凝患者中,HBF(30 mmol/l HCO3-)组至少一次pH excursion率第一期为52%、第二期为48%,LBF(22 mmol/l HCO3-)组分别为41%和34%。
  • HBF组至少一次HCO3- excursion率第一期为68%、第二期为73%,LBF组分别为43%和43%。
  • 校正后HBF较LBF的至少一次pH excursion OR为1.78(95% CI 1.12-2.82;p=0.015),HCO3- excursion OR为3.60(95% CI 2.16-5.99;p<0.001)。
  • 酸中毒患者pH正常化时间在HBF与LBF之间无显著差异(p=0.102),低HCO3-患者HCO3-正常化时间亦无显著差异(p=0.468)。

适用人群与场景

  • 接受CVVH联合局部枸橼酸抗凝治疗的患者,共88例,单中心。

处置流程与药物剂量

  • LBF为含22 mmol/l HCO3-的置换液,HBF为含30 mmol/l HCO3-的置换液。
  • 患者随机先接受LBF或HBF治疗48小时(第一期),随后交叉至另一液体再治疗48小时(第二期)。

研究设计与关键结果

  • 研究类型:前瞻性、随机、对照、开放标签、交叉、单中心试验;样本量88例;干预为CVVH联合局部枸橼酸抗凝下使用LBF(22 mmol/l HCO3-)或HBF(30 mmol/l HCO3-),交叉设计。
  • 至少一次pH excursion率:HBF组第一期52%、第二期48%,LBF组第一期41%、第二期34%。
  • 至少一次HCO3- excursion率:HBF组第一期68%、第二期73%,LBF组第一期43%、第二期43%。
  • 校正OR:pH excursion HBF vs LBF为1.78(95% CI 1.12-2.82;p=0.015);HCO3- excursion HBF vs LBF为3.60(95% CI 2.16-5.99;p<0.001)。
  • 酸中毒患者pH正常化时间HBF与LBF无显著差异(p=0.102);低HCO3-患者HCO3-正常化时间HBF与LBF无显著差异(p=0.468)。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验(交叉设计)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在CVVH联合局部枸橼酸抗凝患者中,LBF(22 mmol/l HCO3-)较HBF(30 mmol/l HCO3-)的pH和HCO3- excursion率显著更低,且酸中毒患者pH正常化时间无显著差异。

指南或共识出处

  • GOV-IDENTIFIER: NCT04071171

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: This study aimed to compare a high (HBF) and low (LBF) bicarbonate (HCO3-) replacement fluid over 96 h after continuous veno-venous hemofiltration (CVVH) initiation using regional citrate anticoagulation to determine which fluid achieved better acid-base balance.

METHODS: In this prospective, randomized, controlled, open-label, cross-over, single-center trial, patients were randomized to initially receive either LBF (22 mmol/l HCO3-) or HBF (30 mmol/l HCO3-) for 48 h (first phase), followed by changing to the other fluid for a further 48 h (second phase). Intracorporeal pH and HCO3- changes were analyzed by calculating the rates of levels outside the standard values (excursion rates). Generalized estimating equations were performed to estimate the odds ratios for at least one pH/HCO3- excursion. Time to normalization within the first phase for pH and HCO3- was assessed using Kaplan-Meier curves and log-rank tests.

RESULTS: A total of 88 patients were included. The rates for at least one pH and HCO3- excursion were higher in patients treated with HBF compared to LBF (pH: first phase 52% vs. 41%; second phase 48% vs. 34%; HCO3-: first phase 68% vs. 43%; second phase 73% vs. 43%). Adjusted odds ratios were 1.78 (95% CI 1.12-2.82; p = 0.015) for pH and 3.60 (95% CI 2.16-5.99; p < 0.001) for HCO3-. The time to normalization of pH in acidotic patients and of HCO3- in patients with low HCO3- did not differ significantly between HBF and LBF (p = 0.102, p = 0.468).

CONCLUSION: LBF showed significantly lower rates of pH and HCO3- excursions compared to HBF and no significant differences to the pH normalization in acidotic patients were observed.

GOV-IDENTIFIER: NCT04071171.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Perschinka F, Köglberger P, Köhler A, et al. Comparison of two different bicarbonate replacement fluids during CVVH with RCA: a prospective, randomized, controlled trial. Intensive Care Med. 2025. PMID: 41247497. doi:10.1007/s00134-025-08175-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。